Exact Sciences Corporation $EXAS Holdings Raised by EFG Asset Management Americas Corp.

EFG Asset Management Americas Corp. increased its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 60.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 37,109 shares of the medical research company’s stock after buying an additional 13,910 shares during the quarter. EFG Asset Management Americas Corp.’s holdings in Exact Sciences were worth $2,030,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Westside Investment Management Inc. raised its position in shares of Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after buying an additional 271 shares in the last quarter. Country Trust Bank bought a new position in shares of Exact Sciences in the second quarter valued at approximately $32,000. Quent Capital LLC acquired a new position in shares of Exact Sciences during the third quarter valued at approximately $48,000. Bollard Group LLC acquired a new position in shares of Exact Sciences during the third quarter valued at approximately $55,000. Finally, OFI Invest Asset Management raised its holdings in Exact Sciences by 241.2% during the third quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company’s stock worth $59,000 after purchasing an additional 767 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Up 0.3%

Shares of EXAS opened at $103.57 on Friday. The business’s 50-day moving average price is $102.83 and its 200 day moving average price is $83.86. The stock has a market capitalization of $19.77 billion, a P/E ratio of -94.15, a P/E/G ratio of 2.36 and a beta of 1.41. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $103.75. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. During the same quarter in the previous year, the business earned ($0.06) EPS. The firm’s quarterly revenue was up 23.1% on a year-over-year basis. Analysts expect that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Analyst Ratings Changes

EXAS has been the subject of a number of research analyst reports. Leerink Partners downgraded Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Craig Hallum downgraded Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price objective on the stock. in a research note on Friday, November 21st. Wells Fargo & Company restated an “equal weight” rating and issued a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a report on Thursday, November 20th. Wolfe Research cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Finally, Jefferies Financial Group lowered Exact Sciences from a “buy” rating to a “hold” rating and lifted their target price for the stock from $90.00 to $105.00 in a report on Monday, November 24th. Twenty-one research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $92.13.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.